Show simple item record

dc.contributor.authorFerro, Charles J.
dc.contributor.authorMark, Patrick B.
dc.contributor.authorKanbay, Mehmet
dc.contributor.authorSarafidis, Pantelis
dc.contributor.authorHeine, Gunnar H.
dc.contributor.authorRossignol, Patrick
dc.contributor.authorMassy, Ziad A.
dc.contributor.authorMallamaci, Francesca
dc.contributor.authorValdivielso Revilla, José Manuel
dc.contributor.authorMalyszko, Jolanta
dc.contributor.authorVerhaar, Marianne C.
dc.contributor.authorEkart, Robert
dc.contributor.authorVanholder, Raymond
dc.contributor.authorLondon, Gerard
dc.contributor.authorOrtiz, Alberto
dc.contributor.authorZoccali, Carmine
dc.date.accessioned2021-04-26T10:17:19Z
dc.date.available2021-04-26T10:17:19Z
dc.date.issued2018
dc.identifier.issn1759-5061 (paper)
dc.identifier.issn1759-507X (electrònic)
dc.identifier.urihttp://hdl.handle.net/10459.1/71146
dc.description.abstractAn increased risk of cardiovascular disease, independent of conventional risk factors, is present even at minor levels of renal impairment and is highest in patients with end-stage renal disease (ESRD) requiring dialysis. Renal dysfunction changes the level, composition and quality of blood lipids in favour of a more atherogenic profile. Patients with advanced chronic kidney disease (CKD) or ESRD have a characteristic lipid pattern of hypertriglyceridaemia and low HDL cholesterol levels but normal LDL cholesterol levels. In the general population, a clear relationship exists between LDL cholesterol and major atherosclerotic events. However, in patients with ESRD, LDL cholesterol shows a negative association with these outcomes at below average LDL cholesterol levels and a flat or weakly positive association with mortality at higher LDL cholesterol levels. Overall, the available data suggest that lowering of LDL cholesterol is beneficial for prevention of major atherosclerotic events in patients with CKD and in kidney transplant recipients but is not beneficial in patients requiring dialysis. The 2013 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for Lipid Management in CKD provides simple recommendations for the management of dyslipidaemia in patients with CKD and ESRD. However, emerging data and novel lipid-lowering therapies warrant some reappraisal of these recommendations.ca_ES
dc.description.sponsorshipAO was supported by Spanish Government ISCIII FEDER funds (PI16/02057, ISCIII-RETIC REDinREN RD16/0009) and Community of Madrid (B2017/BMD-3686 CIFRA2-CM).ca_ES
dc.language.isoengca_ES
dc.publisherNature Researchca_ES
dc.relation.isformatofVersió postprint del document publicat a: https://doi.org/10.1038/s41581-018-0072-9ca_ES
dc.relation.ispartofNature Reviews Nephrology, 2018, vol. 14, núm. 12, p. 727-749ca_ES
dc.rights(c) Nature, 2018ca_ES
dc.subject.otherRonyons -- Malaltiesca_ES
dc.subject.otherLípidsca_ES
dc.titleLipid management in patients with chronic kidney diseaseca_ES
dc.typeinfo:eu-repo/semantics/articleca_ES
dc.type.versioninfo:eu-repo/semantics/acceptedVersionca_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessca_ES
dc.identifier.doihttps://doi.org/10.1038/s41581-018-0072-9


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record